SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:umu-97219"
 

Search: id:"swepub:oai:DiVA.org:umu-97219" > One course of adjuv...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Tandstad, T.St Olavs University Hospital, Norway (author)

One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group

  • Article/chapterEnglish2014

Publisher, publication year, extent ...

  • Elsevier BV,2014
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:umu-97219
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-97219URI
  • https://doi.org/10.1093/annonc/mdu375DOI
  • https://lup.lub.lu.se/record/4614926URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-239383URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-112815URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:130075034URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|National Cancer Fund of Sweden
  • The SWENOTECA group treated 517 clinical stage I nonseminoma patients with one course of adjuvant BEP in a prospective study. The median follow-up is 7.9 years. One course of adjuvant BEP reduced the risk of relapse by over 90%. The relapse rates were 1.6% in low-risk disease and 3.2% in high-risk disease. One course of adjuvant BEP should be considered a standard adjuvant treatment option.SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin (BEP). The aim has been to reduce the risk of relapse, sparing patients the need of toxic salvage treatment. Initial results on 312 patients treated with one course of adjuvant BEP, with a median follow-up of 4.5 years, have been previously published. We now report mature and expanded results. In a prospective, binational, population-based risk-adapted treatment protocol, 517 Norwegian and Swedish patients with CS I nonseminoma received one course of adjuvant BEP. Patients with lymphovascular invasion (LVI) in the primary testicular tumor were recommended one course of adjuvant BEP. Patients without LVI could choose between surveillance and one course of adjuvant BEP. Data for patients receiving one course of BEP are presented in this study. At a median follow-up of 7.9 years, 12 relapses have occurred, all with IGCCC good prognosis. The latest relapse occurred 3.3 years after adjuvant treatment. The relapse rate at 5 years was 3.2% for patients with LVI and 1.6% for patients without LVI. Five-year cause-specific survival was 100%. The updated and expanded results confirm a low relapse rate following one course of adjuvant BEP in CS I nonseminoma. One course of adjuvant BEP should be considered a standard treatment in CS I nonseminoma with LVI. For patients with CS I nonseminoma without LVI, one course of adjuvant BEP is also a treatment option.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Ståhl, OlofLund University,Lunds universitet,Reproduktionsmedicin, Malmö,Forskargrupper vid Lunds universitet,Reproductive medicine, Malmö,Lund University Research Groups,Skåne University Hospital, Sweden(Swepub:lu)kir-ost (author)
  • Håkansson, UlfLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine,Skåne University Hospital, Sweden(Swepub:lu)kir-uha (author)
  • Dahl, O.University of Bergen, Norway; Haukeland Hospital, Norway (author)
  • Haugnes, H. S.University of Tromso, Norway; University Hospital North Norway, Norway (author)
  • Klepp, O. H.Alesund Hospital, Norway (author)
  • Langberg, C. W.Oslo University Hospital, Norway (author)
  • Laurell, AnnaUppsala universitet,Enheten för onkologi,University of Uppsala Hospital, Sweden(Swepub:uu)annajohn (author)
  • Oldenburg, J.Oslo University Hospital, Norway (author)
  • Solberg, A.St Olavs University Hospital, Norway (author)
  • Söderström, KarinThe Cancer Clinic, Norrland University Hospital, Umeå,Norrland University Hospital, Sweden(Swepub:umu)kansom97 (author)
  • Cavallin-Ståhl, EvaLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital, Sweden(Swepub:lu)onk-ecs (author)
  • Stierner, U.Sahlgrens University Hospital, Sweden (author)
  • Wahlquist, R.Oslo University Hospital, Norway (author)
  • Wall, NajmeÖstergötlands Läns Landsting,Linköpings universitet,Avdelningen för kliniska vetenskaper,Hälsouniversitetet,Onkologiska kliniken US(Swepub:liu)najwa86 (author)
  • Cohn-Cedermark, G.Karolinska Institutet (author)
  • St Olavs University Hospital, NorwayReproduktionsmedicin, Malmö (creator_code:org_t)

Related titles

  • In:Annals of Oncology: Elsevier BV25:11, s. 2167-21720923-75341569-8041

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view